Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: Promising diagnostic tools in melanocytic lesions

American Journal of Dermatopathology

Volumn 33, Issue 4, 2011, Pages 361-370

  Nielsen, Patricia Switten ^a,b   Riber Hansen, Rikke ^a   Steiniche, Torben ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

Author keywords

HMB45; immunohistochemistry; Ki67; melanoma; nevus

Indexed keywords

KI 67 ANTIGEN; MELAN A; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOCLONAL ANTIBODY HMB 45;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE MARKER; FEMALE; HALO NEVUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STAINING; TUMOR DIAGNOSIS;

DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MART-1 ANTIGEN; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MIDDLE AGED; NEOPLASM PROTEINS; NEVUS; SKIN NEOPLASMS; SKIN ULCER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79958249263     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3182120173     Document Type: Article

References (26)

1. McCarthy SW, Scolyer RA. Melanocytic lesions of the face: diagnostic pitfalls. Ann Acad Med Singapore. 2004;33:3-14.
2. Li LX, Crotty KA, McCarthy SW, et al. A zonal comparison of MIB1- Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2000;22:489-495. (Pubitemid 32054841)
3. Kapur P, Selim MA, Roy LC, et al. Spitz nevi and atypical Spitz nevi/ tumors: a histologic and immunohistochemical analysis. Mod Pathol. 2005;18:197-204. (Pubitemid 40188626)
4. Kornstein MJ, Byrne SP. The medicolegal aspect of error in pathology: a search of jury verdicts and settlements. Arch Pathol Lab Med. 2007;131: 615-618. (Pubitemid 46564437)
5. Ivan D, Prieto VG. Use of immunohistochemistry in the diagnosis of melanocytic lesions: applications and pitfalls. Future Oncol. 2010;6: 1163-1175.
6. Prieto VG, Shea CR. Use of immunohistochemistry in melanocytic lesions. J Cutan Pathol. 2008;35(2 suppl):1-10.
7. Rudolph P, Schubert C, Schubert B, et al. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. J Am Acad Dermatol. 1997;37: 169-178. (Pubitemid 27355700)
8. Bergman R, Malkin L, Sabo E, et al. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J Am Acad Dermatol. 2001;44:500-504. (Pubitemid 32199972)
9. Chorny JA, Barr RJ, Kyshtoobayeva A, et al. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions. Mod Pathol. 2003;16:525-529. (Pubitemid 36718432)
10. Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35:433-444. (Pubitemid 351519417)
11. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30:117-122. (Pubitemid 351441982)
12. Puri PK, Valdes CL, Burchette JL, et al. Accurate identification of proliferative index in melanocytic neoplasms with Melan-A/Ki-67 double stain. J Cutan Pathol. 2010;37:1010-1012.
13. Bergman R, Dromi R, Trau H, et al. The pattern of HMB-45 antibody staining in compound Spitz nevi. Am J Dermatopathol. 1995;17:542-546. (Pubitemid 26010177)
14. Gundersen HJ, Bendtsen TF, Korbo L, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS. 1988;96:379-394.
15. Altman DG. Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Books; 2000.
16. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857-872. (Pubitemid 28185165)
17. Lebe B, Pabuccuoglu U, Ozer E. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions. Appl Immunohistochem Mol Morphol. 2007;15: 160-164. (Pubitemid 46828222)
18. Alkushi A, Abdul-Rahman ZH, Lim P, et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol. 2005;29:295-304. (Pubitemid 40321964)
19. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med. 2006;130:1448-1453.
20. Van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004;57:675-681. (Pubitemid 38901478)
21. Moretti S, Spallanzani A, Chiarugi A, et al. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J Am Acad Dermatol. 2001;44:188-192. (Pubitemid 32172178)
22. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-8056. (Pubitemid 46657407)
23. Vogt T, Zipperer KH, Vogt A, et al. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology. 1997;30:57-63. (Pubitemid 27072449)
24. Henrique R, Azevedo R, Bento MJ, et al. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. J Am Acad Dermatol. 2000;43:991-1000.
25. Hazan C, Melzer K, Panageas KS, et al. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer. 2002;95:634-640. (Pubitemid 34810190)
26. Ilmonen S, Hernberg M, Pyrhonen S, et al. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Melanoma Res. 2005;15: 375-381. (Pubitemid 41558947)